Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24926131 | 0.90 | LMNA (0.30) | TSHR | |
| SCHEMBL18713029 | 0.83 | USP2 (0.36) | USP2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL23555259 | 0.82 | CYP3A4 (0.32) | USP2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL25932907 | 0.81 | CYP3A4 (0.35) | USP2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL19634088 | 0.80 | CYP3A4 (0.37) | USP2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL25942953 | 0.80 | CYP2D6 (0.35) | CYP2D6CYP1A2 | |
| SCHEMBL23594083 | 0.78 | USP2 (0.31) | USP2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL19429912 | 0.75 | HTR1A (0.33) | USP2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL24410948 | 0.73 | KDM4E (0.32) | TSHR | |
| SCHEMBL23770908 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | USP2 22/4885CYP3A4 4366/4885CYP2D6 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.